Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Mar 15, 2023
Sam Lee is the Co-CEO and President of Cocrystal Pharma, focused on pandemic viruses and seasonal influenza to develop a drug that is cross-spectrum with a high barrier to drug resistance. Using computational data, as well as high-resolution X-ray data, their platform allows options for newly emerging viruses that also address potency and combination treatment options.
Sam explains, "We just completed the Phase I study. In the Phase I study, we demonstrated the favorable safety and tolerability of this compound, CC-42344. We designed this compound for pandemic and seasonal influenza A infection. Particularly, this compound is highly sensitive to the avian influenza strain, potentially an emerging pandemic strain."
"I think with antiviral drug development, you always have to think about three important things. One is the cross-spectrum, which covers the existing viruses. For example, in the influenza case, influenza H1N1, H2, and H3. And beyond seasonal influenza viruses are pandemic viruses, H5 and H7, and potentially emerging avian flu. So we want to cover all these viruses. That's a really important goal."
"Once you achieve good potency and cross-spectrum activity, then you want to solve the pharmacology. It's going to be a once-a-day drug with the excellent drug resistance. Drug resistance is a really key contribution using our platform approach. "
@CocrystalPharma $COCP #PandemicFlu #CC42344 #SeasonalInfluenzaA #Flu #Pandemic
